@FierceBiotech: Welcome Galen Moore, the new managing editor of FierceBiotech, FiercePharma and FierceMedicalDevices! | Follow @FierceBiotech
@JohnCFierce: Whoa, FDA gets mighty cross with 23andMe, tackles Anne Wojcicki. Want to see what angry regulators look like? FDA warning letter | Follow @JohnCFierce
@DamianFierce: With $43M in the bank, startup Editas sets off in pioneering "molecular surgery" field. News | Follow @DamianFierce
@EmilyMFierce: Biota scraps preclinical antibiotics program as antimicrobial resistance grows. Story | Follow @EmilyMFierce
> Faced with falling sales, Sanofi ($SNY) CEO Chris Viehbacher has vowed to invest up to about $2.7 billion a year in new acquisitions. Top fields of interest: diabetes, vaccines, animal health and rare disease. Story
> Cambridge, MA-based Alnylam ($ALNY) is picking up a $7 million milestone from Genzyme for its work on the ATTR drug patisiran. Story
> Progenics ($PGNX) says it will resume a Phase IIb study of Azedra, a rare endocrine tumor drug. Release
@FierceMedDev: A French start-up nailed some major financing for its retinal implant - a $20M-plus Series A. Story | Follow @FierceMedDev
@MarkHFierce: TB Dx maker Oxford Immunotec launched a relatively-modest IPO but it gained steam in initial trading. Friday's story | Follow @MarkHFierce
> Under Icahn's pressure, Hologic's M&A prospects heat up. Story
> Key piece of Roche, Novo Nordisk diabetes device deal nears EU approval. Article
> Sorin CE nails CE mark for extra-large size of sutureless aortic valve. Item
Pharma News
@FiercePharma: The weekend's best-read special report: Top 10 Pharma Companies by 2012 Revenue. Report | Follow @FiercePharma
@EricPFierce: FDA approves, buys GSK vaccine in case of H1N1 pandemic. More | Follow @EricPFierce
@CarlyHFierce: Voters in Switzerland turn down strict CEO pay limits. Story | Follow @CarlyHFierce
> 2014 deal outlook: Sanofi eyes $2.7B in buys; AZ analysts figure on bigger M&A. Report
> Who leaked the scary Copaxone numbers? Teva aims to find out. Story
> J&J's newly approved Olysio to rival Merck and Vertex entries in hep C market. Item
CRO News
> Indian CROs leap into U.S. with joint venture. News
> Pharmacyclics, J&J pick Catalent for blockbuster cancer drug. More
> ResearchDx reaches into India for contract diagnostics work. News
> Covance taps NeoGenomics for cancer trial diagnostics. Article
> Vietnam taps Quintiles to up its stake in global trials. Story
Biotech IT News
> Google begins hiring team to lead Calico. More
> Life sciences IT execs plan business intelligence spending blitz. News
> Lilly, Novartis and Pfizer sign up to improve ClinicalTrials.gov. Story
> Report finds inexcusable failings in government cybersecurity. Piece
> Novartis looks to data management vendors to slash costs. Article